HELSINKI, Finland, November 2021. Finnish bioinformatics software company Euformatics has today announced that its variant surveillance software tool now provides updated classification options for the SARS-CoV-2 virus, including the recently discovered Omicron variant.
The software tool, funded by Amazon Web Services and first deployed by SYNLAB in July 2021, provides users with information both of the molecular-level variants of the virus in a sample, as well as an automatic classification of the virus according to known variants. Initially deployed as the Delta variant of the SARS-CoV-2 virus was making headlines around the world, the software today added the functionality to classify the virus as the newest Omicron variant. The upgrade comes at a timely moment, as governments around the world scramble to minimise the spread of the variant.
For laboratories using NGS technology to sequence positive COVID-19 samples for governments or state-level institutions, the software provides a quick and easy way to analyse files and classify the virus before passing the data on to supranational bodies. Understanding how different virus variants spread and at what speed greatly affects response to the pandemic and influences how future outbreaks of the virus can potentially be predicted and prevented.
Euformatics CEO, Tommi Kaasalainen, explained “As the COVID-19 virus continues to mutate, governments and the international community as a whole need to be able to respond as quickly as possible to new variants. By being able to quickly classify positive virus samples while at the same time gaining a better understanding of the molecular level changes puts more power in the hands of virologists to tackle the virus in good time before a wide-scale spread of more dangerous variants.”
Euformatics is a Finnish software company that specialises in high standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer, common or rare disease diagnostics. At present, our core solution is the omnomics Suite which includes omnomicsNGS; for clinical analysis and reporting of patient NGS data, and omnomicsQ; for NGS data quality management.
For more information, please visit our website www.euformatics.com